Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab SC in Previously Treated STK11/LKB1 Mutated NSCLC
NCT05807048Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Jun 2023
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in non-small cell lung cancer (NSCLC), sponsored by NYU Langone Health. Started Jun 2023; status: completed.
02
Drugs
daratumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05807048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05807048.